A Retrospective, Multicenter and Observational Study of Nivolumab Monotherapy Treatment in Subjects With Advanced or Metastatic Squamous (Sq) or Non-Squamous (Non-Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimens for the Treatment of Stage IIIb/IV NSCLC Within the Expanded Access Program (EAP) in SPAIN
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 26 Apr 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms NIVEX
- 23 Apr 2018 Planned End Date changed from 1 Mar 2018 to 15 May 2018.
- 23 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Oct 2017 Status changed from not yet recruiting to recruiting.